Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Adc Therapeutics Sa
(NY:
ADCT
)
3.630
-0.190 (-4.97%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Adc Therapeutics Sa
< Previous
1
2
3
4
5
6
7
8
Next >
ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma
July 20, 2022
From
ADC Therapeutics SA
Via
Business Wire
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial
July 11, 2022
From
ADC Therapeutics SA
Via
Business Wire
Why ADC Therapeutics Shares Are Rising Today
July 08, 2022
ADC Therapeutics SA (NYSE: ADCT) shares are trading higher by 11.56% to $10.23 Friday afternoon after the company entered into an exclusive license agreement with Swedish Orphan Biovitrum for the...
Via
Benzinga
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
July 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
ADC Therapeutics, Sobi Ink European Licensing Pact For Lymphoma Drug
July 08, 2022
Via
Benzinga
Analyst Ratings for ADC Therapeutics
May 10, 2022
Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter:
Via
Benzinga
ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories
July 08, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors
July 01, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents
June 29, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics: Q1 Earnings Insights
May 09, 2022
ADC Therapeutics (NYSE:ADCT) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications
June 13, 2022
Via
Benzinga
ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer
June 13, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma
June 10, 2022
From
ADC Therapeutics
Via
Business Wire
ADC Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2022
From
ADC Therapeutics SA
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
May 17, 2022
On Tuesday, 123 stocks made new 52-week lows.
Via
Benzinga
ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress
May 12, 2022
From
ADC Therapeutics SA
Via
Business Wire
RBC Capital Maintains Outperform Rating for ADC Therapeutics: Here's What You Need To Know
May 10, 2022
RBC Capital has decided to maintain its Outperform rating of ADC Therapeutics (NYSE:ADCT) and lower its price target from $34.00 to $30.00. Shares of ADC Therapeutics are trading down 1.34% over the...
Via
Benzinga
Mid-Afternoon Market Update: Crude Oil Down 6%; Palantir Technologies Shares Slide
May 09, 2022
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 400 points on Monday.
Via
Benzinga
Mid-Day Market Update: Nasdaq Dips 450 Points; Hemisphere Media Group Shares Surge
May 09, 2022
U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping around 450 points on Monday.
Via
Benzinga
90 Biggest Movers From Yesterday
May 10, 2022
Gainers
Via
Benzinga
40 Stocks Moving In Monday's Mid-Day Session
May 09, 2022
Gainers
Via
Benzinga
ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 09, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Announces CEO Transition
May 09, 2022
From
ADC Therapeutics SA
Via
Business Wire
Earnings Outlook For ADC Therapeutics
May 06, 2022
ADC Therapeutics (NYSE:ADCT) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that ADC...
Via
Benzinga
ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
May 04, 2022
From
ADC Therapeutics SA
Via
Business Wire
How To Attend ADC Therapeutics Q1 2022 Earnings Conference Call
May 04, 2022
ADC Therapeutics (NYSE:ADCT) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. How to Attend ADC Therapeutics (ADCT) Conference Call Follow this link to...
Via
Benzinga
ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022
May 03, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services
April 04, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021
March 17, 2022
From
ADC Therapeutics SA
Via
Business Wire
Cantor Fitzgerald Cuts ADC Therapeutics Price Target On 'Repositioned Zynlonta Pipeline Strategy'
March 04, 2022
Following Q4 FY21 results, Cantor Fitzgerald has lowered the price target on ADC Therapeutics SA (NASDAQ: ADCT) to $26 from $45 and keeps an Overweight rating...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.